Investor Relations
Corporate Profile
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
Webcast ImageWebcast
Obalon Therapeutics, Inc. at UBS Global Healthcare Conference (Replay)
05/21/18 at 9:30 a.m. ET
Obalon Therapeutics, Inc. at UBS Global Healthcare Conference
Monday, May 21, 2018 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
IR Kit
Obalon Presentation
First Quarter 2018 Press Release
Third Quarter 2017 10Q
2017 10K
424B Filing

Stock Quote
OBLN (Common Stock) $2.54  + 0.04 (1.60%)
ExchangeNASDAQ
Volume36,275
Today's Open$2.52
Previous Close$2.50
Data as of 05/25/18 4:00 p.m. ET    Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.


Stock Chart
Stock chart for: OBLN.O.  Currently trading at $2.54 with a 52 week high of $11.95 and a 52 week low of $2.46.

Upcoming Events
There are currently no events scheduled.

IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling